Detalhe da pesquisa
1.
First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non-muscle invasive bladder cancer indicates high tolerability and local immunological activity.
Cancer Immunol Immunother
; 70(9): 2727-2735, 2021 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-33837852
2.
Removal of EpCAM-positive tumor cells from blood collected during major oncological surgery using the Catuvab device- a pilot study.
BMC Anesthesiol
; 21(1): 261, 2021 10 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34715784
3.
Randomised phase II trial to investigate catumaxomab (anti-EpCAM × anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer.
Br J Cancer
; 119(3): 296-302, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29988111
4.
Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies.
Br J Haematol
; 169(1): 90-102, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25495919
5.
Potential of the trifunctional bispecific antibody surek depends on dendritic cells: rationale for a new approach of tumor immunotherapy.
Mol Med
; 19: 54-61, 2013 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-23552725
6.
Expression of epithelial cell adhesion molecule in paired tumor samples of patients with primary and recurrent serous ovarian cancer.
Int J Gynecol Cancer
; 23(5): 797-802, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23694980
7.
Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites.
Int J Cancer
; 130(9): 2195-203, 2012 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21702044
8.
Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model.
J Transl Med
; 10: 219, 2012 Nov 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-23134699
9.
Cancer therapy with trifunctional antibodies: linking innate and adaptive immunity.
Future Oncol
; 8(1): 73-85, 2012 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-22149036
10.
Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model.
Front Immunol
; 13: 1023206, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36700232
11.
Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial.
Onkologie
; 34(3): 101-8, 2011.
Artigo
em Inglês
| MEDLINE | ID: mdl-21358214
12.
GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma.
J Immunother Cancer
; 9(7)2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34285106
13.
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.
Int J Cancer
; 127(9): 2209-21, 2010 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-20473913
14.
Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients.
Br J Clin Pharmacol
; 69(6): 617-25, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20565453
15.
Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lymphocytes and trifunctional bispecific antibody.
Exp Hematol
; 36(8): 997-1003, 2008 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-18495330
16.
Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 x anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels.
Int J Cancer
; 123(5): 1181-9, 2008 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-18546289
17.
Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.
Clin Cancer Res
; 13(13): 3899-905, 2007 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17606723
18.
Biodistribution and radioimmunotherapy of SCCHN in xenotransplantated SCID mice with a 131I-labelled anti-EpCAM monoclonal antibody.
Anticancer Res
; 27(1A): 431-6, 2007.
Artigo
em Inglês
| MEDLINE | ID: mdl-17352264
19.
Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer.
Clin Cancer Res
; 12(10): 3085-91, 2006 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16707606
20.
Potent CD4+ T cell-associated antitumor memory responses induced by trifunctional bispecific antibodies in combination with immune checkpoint inhibition.
Oncotarget
; 8(3): 4520-4529, 2017 Jan 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-27966460